Compare Illumina, Inc. (ILMN) vs Trip.com Group Ltd (TCOM) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Illumina, Inc. vs Trip.com Group Ltd — how do they compare? Illumina, Inc. trades at $191.03 (market cap $27.94B), while Trip.com Group Ltd trades at $43.66 (market cap $28.12B). The key difference: Illumina, Inc. and Trip.com Group Ltd are close in size by market cap, and Trip.com Group Ltd pays a 0.42% dividend while Illumina, Inc. pays none. Which is the better fit depends on your goals.
| ILMN | TCOM | |
|---|---|---|
Market Cap | $27.94B | $28.12B |
Sector | Health | Consumer Cyclical |
52-Week High | $194.33 | $78.96 |
52-Week Low | $91.00 | $39.84 |
Enterprise Value | $29.33B | $20.82B |
Dividend Yield | — | 0.42% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Illumina (ILMN) trades at $185.36, down 0.69% on the day, with a bullish technical signal from moving averages. The stock shows strong profitability with a 19.42% net income margin and has beaten EPS estimates for three consecutive quarters. Recent news highlights expansion of the Billion Cell Atlas program and upcoming Q2 2026 earnings on July 30.
Outlook remains positive with 51% analyst buy ratings, though the current price exceeds the $178 consensus target. Key risks include competitive pressure from Roche's new sequencer and China market weakness. Earnings growth and cost control initiatives support upside potential, but valuation multiples suggest limited near-term appreciation.
TCOM trades at $44.15, up 4.0% over 24 hours but facing near-term pressure after recent earnings misses and regulatory scrutiny. The stock shows strong fundamentals with a P/E of 6.38 and net income margin of 48.65%, supported by robust revenue growth from $20.0B in 2022 to $62.4B in 2025. Technical indicators signal a bearish trend with resistance at $44-$45, while analyst consensus remains bullish with a $56.72 price target despite recent guidance concerns.
The outlook balances high profitability and undervaluation against regulatory risks and slowing growth guidance. Investment appeal lies in its dominant market position and cash flow strength, but investors face headwinds from antitrust investigations and margin pressure. The stock's current discount to analyst targets presents opportunity if execution improves.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Illumina, Inc.
Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →About Trip.com Group Ltd
Trip.com is the largest online travel agent in China and is positioned to benefit from the country's rising demand for higher-margin outbound travel as passport penetration is only 12% in China. The company generated about 78% of sales from accommodation reservations and transportation ticketing in 2020. The rest of revenue comes from package tours and corporate travel. Prior to the pandemic in 2019, the company generated 25% of revenue from international business, which is important to its margin expansion. Most of sales come from websites and mobile platforms, while the rest come from call centers. The competes in a crowded OTA industry in China, including Meituan, Alibaba-backed Fliggy, Toncheng, and Qunar. The company was founded in 1999 and listed on the Nasdaq in December 2003.
Read more on TCOM →
